Autoimmune diseases are driven primarily by adaptive immune responses that produce autoantibodies and autoreactive T cells, while autoinflammatory diseases arise from dysregulation of the innate immune system and inflammasome activation. Distinguishing them matters because diagnostic tests, therapies, and prognosis differ substantially.
Diagnostic tests and biomarkers
Routine serology is central for autoimmune disease detection. Positive tests such as antinuclear antibodies or disease-specific autoantibodies support an autoimmune mechanism and are recommended in rheumatology practice by authors such as Daniel L. Kastner National Institutes of Health, who has described the contrasting molecular bases of innate versus adaptive immune disorders. Acute phase reactants like ESR and CRP rise in both groups but very high, recurrent febrile inflammatory spikes with neutrophil predominance point toward autoinflammatory pathology. Genetic testing is decisive for many monogenic autoinflammatory syndromes: mutations in genes such as MEFV or NLRP3 are diagnostic and guide therapy. Rachel Goldbach-Mansky National Institute of Arthritis and Musculoskeletal and Skin Diseases has documented the clinical utility of genetic panels and cytokine profiling, noting that elevated interleukin-1 beta or interleukin-18 concentrations favor an autoinflammatory process. Complement levels, immunoglobulin quantitation, and type I interferon signatures can further stratify cases, particularly when features overlap.
Clinical context and consequences
Clinical pattern recognition remains essential. Autoimmune disorders commonly present with organ-specific chronic inflammation, lymphocytic infiltrates on biopsy, and gradual tissue damage mediated by adaptive immunity. Autoinflammatory diseases often show early-onset periodic fever, systemic inflammation without high-titer autoantibodies, and rapid response to innate-targeted therapies. Amos Livneh Sheba Medical Center has characterized familial Mediterranean fever as an archetypal autoinflammatory disease with founder effects in Mediterranean populations, illustrating how territorial genetics affect diagnostic yield. Therapeutic consequence is direct: autoimmune conditions frequently require immunomodulation with disease-modifying agents, whereas many autoinflammatory syndromes respond to cytokine blockade such as IL-1 blockade.
In practice the best approach integrates detailed history and exam, targeted serology and biopsy when indicated, and early use of genetic testing and cytokine assays when autoinflammatory disease is suspected. Overlap syndromes exist, so multidisciplinary evaluation and access to genetic diagnostics are critical to avoid misclassification and to optimize treatment and outcomes.